SUNNYVALE, California,
May 11, 2017 /PRNewswire/ --
Studies Show the System
Provides Excellent Outcomes Throughout the
Cancer Treatment Journey, from
Primary Cases to Recurrence and
Metastatic Disease
Accuray Incorporated (NASDAQ: ARAY) announced today that studies
on the clinical use of the leading-edge CyberKnife® System continue
to demonstrate its benefits across a wide range of cancer
indications and stages in the cancer treatment journey. More than
50 studies were presented during poster and oral sessions at the
36th Annual European Society for Radiotherapy &
Oncology (ESTRO) Meeting in Vienna,
Austria, May 5 - 9, 2017. Some
of the studies presented show long-term efficacy and safety with
median follow-up exceeding five years.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://mma.prnewswire.com/media/510538/Accuray_CyberKnife_Treatment_Delivery_System.jpg
)
CyberKnife
stereotactic body radiation
therapy (SBRT) is
used worldwide for effective
management of prostate cancer
- Safety, efficacy, and quality of life (QOL) outcomes were
reported for 309 patients with low- or intermediate-risk prostate
cancer receiving SBRT administered with the CyberKnife System. The
study showed cancer control was excellent in both risk groups with
97% of patients free from recurrence at five years. Transient
decreases in bowel and urinary QOL were observed, but returned to
baseline. Twenty-one U.S. hospitals participated in this
prospective study including Swedish Cancer Institute in
Seattle, Washington and Beth
Israel Deaconess Medical Center in Boston, Massachusetts.
- A study evaluated the long-term results of CyberKnife prostate
SBRT delivered either on consecutive days or every other day. The
treatment was well-tolerated with high rates of five-year
biochemical relapse free survival (BRFS). Low rates of toxicity
were unaffected by the treatment schedule. The research was
conducted at the Hacettepe University in Ankara, Turkey.
- Long-term results of another study conducted on 329 patients
with low- and intermediate-risk prostate cancer revealed that
extreme hypofractionated radiotherapy delivered with the CyberKnife
System is well tolerated and safe with comparable late toxicity as
other treatment modalities. Clinicians of the Erasmus MC Cancer
Institute, in Rotterdam
(The Netherlands) conducted the
study.
The CyberKnife System
provides benefits for
primary
cases,
recurrent
and metastatic
diseases
Recurrent Disease
- Although re-irradiation of recurrent diseases can be
challenging in clinical practice, four European studies confirmed
its feasibility in prostate and rectal cancer, as well as in
recurrent high grade gliomas. These studies concluded that
re-irradiation with the CyberKnife System is well-tolerated and
effective in controlling local recurring disease.
- A study of CyberKnife SBRT for oligorecurrent liver disease
showed treatment was well-tolerated and resulted in favorable
survival data. Clinicians at three European hospitals conducted the
research.
- A study evaluated the efficacy and toxicity of single fraction
SBRT for isolated nodal failure in prostate cancer patients, after
primary surgical or radiation treatment. Treatment with the
CyberKnife System provided excellent tolerability and promising
biochemical control at 13 months' follow-up. Research was conducted
at three Italian hospitals.
Metastatic Disease
- A study of patients with solitary extracranial metastases from
gynecologic malignancies demonstrated that SBRT delivered with the
CyberKnife® System is well-tolerated and highly effective. An
excellent 5-year local control of 93.7% was achieved in patients
with classical ovarian and uterine primary tumors. Research was
conducted at Georgetown University
Hospital in Washington, DC.
- Another study evaluated 206 patients with 326 inoperable
pulmonary oligometastases, from colorectal tumors, lung cancers,
melanoma, sarcoma, breast carcinoma, and from other sites, treated
with SBRT. This long-term follow-up study showed good local control
(83% at 2-years and 73% at 5-years) and overall survival (2, 3, and
5-year OS rates were 63%, 47% and 30%, respectively), as well as
low rates of serious toxicity. Research was conducted at Erasmus
MC-Daniel den Hoed Cancer Center in Rotterdam (The
Netherlands).
Technical innovations
improve the delivery of
radiation therapy
- New studies reinforce previous data demonstrating intracranial
and extracranial treatments delivered using the CyberKnife System
InCise™ Multileaf Collimator result in comparable target coverage
and organ-at-risk sparing to the Iris™ Collimator, while
significantly reducing treatment times (15% to 47% reduction
compared to Iris plans depending on tumor type). Research was
conducted at six European hospitals.
- The first study to use three-dimensional performance analysis
of the Synchrony® Respiratory Tracking System found it successfully
tracks lung tumors regardless of the amplitude of movement.
Research was conducted at Hacettepe University in Ankara, Turkey.
The CyberKnife System was designed to deliver treatment beams of
different size and shape from hundreds of non-coplanar, isocentric
or non-isocentric angles around the patient, enabling the clinician
to deliver high-quality treatment plans with extreme precision,
sparing surrounding healthy tissue and structures. The system's
tracking capabilities eliminate the need for gating techniques and
restrictive head frames, providing greater comfort for the
patient.
"I am proud to see that the unique capabilities of our radiation
therapy delivery systems are enabling clinicians to develop
innovative approaches for delivering radiation treatments which
make a real difference in their patients' lives," said Fabienne
Hirigoyenberry, VP Global Medical and Scientific Affairs of
Accuray. "Since 1994 when the first patient was treated with the
CyberKnife System, it has set the bar for delivering precise
radiation treatments while avoiding healthy tissue. The data
presented at ESTRO 36 reinforce the system's benefits and show it
is increasingly being used to treat a wide range of cancer
cases."
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology
company that develops, manufactures, and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed from
time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016, February 3, 2017, and May
5, 2017, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.